NN 9926
Alternative Names: GLP-1 SG GIPET; Long-acting GLP-1 analogue - Novo Nordisk; NN-9926; NNC 0113-0987; Non-invasive GLP-1 - Novo Nordisk; OG-987-GT; SG GIPETLatest Information Update: 14 Dec 2020
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Germany (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in United Kingdom (IV)